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Abstract
Background: Gliomas display a high degree of intratumor heterogeneity, including 
changes in physiological parameters and lipid composition of the plasma membrane, 
which may contribute to the development of drug resistance. Biophysical interactions 
between therapeutic agents and the lipid components at the outer plasma membrane 
interface are critical for effective drug uptake. Amphipathic molecules such as perillyl 
alcohol (POH) have a high partition coefficient and generally lead to altered lipid 
acyl tail dynamics near the lipid-water interface, impacting the lipid bilayer structure 
and transport dynamics. We therefore hypothesized that glioma cells may display 
enhanced sensitivity to POH-induced apoptosis due to plasma membrane alterations, 
while in non-transformed cells, POH may be expelled through thermal agitation. 
Methods: Interactions between POH and the plasma membrane was studied using 
molecular dynamics simulations. In this phase I/II trial, we set up to evaluate the 
clinical effectiveness of long-term (up to 5 years) daily intranasal administration 
of POH in a cohort of 19 patients with low-grade glioma (LGG). Importantly, in a 
series of clinical studies previously published by our group, we have successfully 
established that intranasal delivery of POH to patients with malignant gliomas is 
a viable and effective therapeutic strategy. 
Results: POH altered the plasma membrane potential of the lipid bilayer of gliomas 
and prolonged intranasal administration of POH in a cohort of patients with LGG 
halted disease progression with virtually no toxicity. 
Conclusion: Altogether, the results suggest that POH-induced alterations of the 
plasma membrane might be contributing to its therapeutic efficacy in preventing 
LGG progression.
Key Words: Chemotherapy for gliomas, intranasal administration, long-term 
survival, membrane potentials, molecular dynamics simulation, perillyl alcohol
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INTRODUCTION
The development of resistance to chemotherapeutic 
agents is commonly observed during the course 
of cancer therapy and represents a major clinical 
challenge.[16] Ultimately, cancer cells may develop a 
multidrug resistant (MDR) phenotype, where they 
become cross‑resistant to a variety of therapeutic agents, 
resulting in failure of standard combination therapies 
and dismal prognosis.[26] Among primary brain tumors, 
malignant gliomas (astrocytoma, glioblastoma) are the 
most common; they spell poor prognosis for the afflicted 
patients because this tumor type frequently becomes 
resistant to standard chemotherapy.[31] Numerous 
chemotherapy trials undertaken have proven to be rather 
ineffective with many disappointing results.
Accumulating evidence shows that proliferation, as well 
progression of human malignant astrocytoma involves 
activation of the Ras oncoprotein.[27,29] In addition to 
its well‑known effects on tumor cell proliferation, the 
Ras‑controlled signal transduction pathway plays a critical 
role in mediating angiogenic signaling; for example, it 
increases expression and secretion of vascular endothelial 
growth factor, a key stimulator of angiogenesis.[28] Ras 
proteins (H‑, K‑, and N‑Ras) belong to the group of 
small GTPases, which are localized at the inner leaflet 
of the plasma membrane.[17] Studies with K‑Ras have 
revealed the dynamic interactions between this protein 
and the plasma membrane, which involve electrostatic 
interactions between negatively charged moieties of 
the membrane and the polybasic region of K‑Ras.[15] In 
addition, an isoprenyl group at the C‑terminus of K‑Ras 
mediates tethering of the protein to the cell membrane.[19] 
It has been established that interaction of Ras proteins 
with the cell membrane represents a prerequisite for 
effective Ras signaling, which relays extracellular signals 
to the cell nucleus, resulting in extensive alterations in 
gene expression and phenotype. Oncogenic Ras mutations 
are known to profoundly affect this signaling process and 
may contribute to the development of drug resistance 
of cancer cells. Therefore, to overcome induction of 
acquired drug resistance, it is important to understand 
the biophysical properties of therapeutic agents and how 
they affect plasma membrane homeostasis.
Literature provides numerous examples where synthetic 
drugs or naturally occurring substances exert biological 
effects via their interactions with the plasma membrane. 
Such interactions may involve disrupting the integrity 
and biophysical properties of the lipid bilayer, increasing 
its permeability, disturbing the conformation of 
membrane proteins, or directly binding to membrane 
lipids.[18,21] Studies with the monoterpene limonene 
and its metabolic products perillyl alcohol (POH) 
and perillaldehyde have shown that these natural 
compounds impact cell membranes as well,[11,34] and it 
is conceivable that such interactions contribute to these 
compounds’ known anti‑inflammatory, anti‑microbial, 
and anti‑cancer effects. Indeed, the amphipathic 
character of POH with its hydrophobic and hydrophilic 
domains makes it readily soluble in biological 
membranes.[23] This property increases the partition 
coefficient and packing along the lipid tail, and leads 
to altered lipid acyl tail dynamics at the lipid‑water 
interface, which will ultimately modify the lipid bilayer 
structure and transport dynamics.
Based on the above‑outlined membrane interactions of 
Ras proteins, in combination with considerations of the 
amphipathic character of POH, it is conceivable that 
POH might play an important role in the inhibition of 
Ras, thereby affecting a key signaling pathway leading to 
pleiotropic outcomes.[20,22] Astrocytoma often manifest 
as low‑grade tumors that subsequently progress to 
higher‑grade tumors, and their advancing malignancy 
may be linked to changes in physiological parameters 
such as plasma membrane potential.[2] In this context, 
a preclinical study showed that astrocytes were cultured 
with POH without toxicity, while the compound 
was cytotoxic to temozolomide (TMZ)‑resistant, 
as well as TMZ‑sensitive glioma cells, and this 
effect was independent of O6‑methylguanine‑DNA 
methyltransferase expression.[5] In fact, our Phase II 
trial studies with recurrent malignant glioma patients 
showed that POH inhalation chemotherapy is safe and 
represents an effective strategy for the noninvasive 
treatment of recurrent malignant glioma.[7‑9] Noteworthy, 
among 198 patients in our study, we observed that 
long‑term treatment (up to 5 years) with daily intranasal 
POH administration as a single chemotherapeutic drug 
improved and stabilized the condition of 19 low‑grade 
gliomas (LGG) patients.
Despite some progress, there remains an urgent 
medical need for cancer treatments that are more 
effective and avoid the development of the MDR 
phenotype. At the same time, it is desirable that such 
treatments are safe and easily tolerated, which usually 
mandates a lack of toxic impact on normal cells. We, 
therefore, investigated the interactions between the 
Ras inhibitor POH and cellular membranes, using 
molecular dynamic (MD) simulations to provide a 
biophysical description as to how lipid bilayer‑mediated 
pharmacological effects might be involved in generating 
therapeutic outcomes of long‑term POH inhalation 
treatment. Prior MD simulations of POH and related 
terpenes showed that the terpenes all partitioned into 
the lipid bilayer, thereby altering membrane properties. 
In this study, we measured the dipole potential of 
the lipid bilayer and found that it was significantly 
modified by POH.
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PATIENTS AND METHODS
Molecular dynamics simulations
The simulations were set up in a manner similar to that 
previously described.[34] In short, a fully hydrated and 
equilibrated 128‑lipid dimyristoylphosphatidylcholine 
(DMPC) bilayer was simulated at 310 K in the NPT 
ensemble for 103 ns. For simulations with POH, 
64 molecules of POH were placed randomly in the 
aqueous phase around the DMPC bilayer, and the 
simulation was run for 220 ns, during which all POH 
molecules partitioned into the lipid bilayer. The 
membrane dipole potential was calculated using Poisson’s 
equation by double integrating the charge density across 
the lipid bilayer:
−∞ −∞
ψ ψ −∞ = − ∫ ∫ 0( ) -  ( ) ´ ( ´ ´ ) ´ ´ /
z z
z dz p z dz e
The potential was symmetrized around the bilayer 
center to correct for overall bilayer translation during the 
simulation.
Clinical study
This clinical study was approved by the Rio de Janeiro 
Federal University Hospital Ethics Committee and the 
Brazilian Ministry of Health (CONEP 9681 Number 124 
25000.009267/2004‑25). It was carried out at the Hospital 
Medical School of the Fluminense Federal University. 
Before inclusion in the protocol, patient signed a written 
informed consent to enroll the Phase I/II clinical trial. 
POH was formulated for inhalation delivery and the 
preparation supplied by the Multidisciplinary Laboratory 
of Pharmaceutical Sciences at Rio de Janeiro Federal 
University. POH (55 mg; 0.3% v/v), was administered by 
inhalation 4 times daily totaling 266.8 mg/daily.
Patient selection
This prospective study was carried out from July 2006 to 
December 2014 with patients attending the outpatient 
Neurosurgical Unit in the Antonio Pedro University 
Hospital and included in the Phase I/II clinical trial to 
assess the efficacy of intranasal administration of the 
POH. Eligibility criteria included patients older than 
18 years with recurrent malignant glioma with at least 
two relapses, measurable contrast‑enhancing tumor image 
on magnetic resonance, Karnofsky index ≥70%, adequate 
hematological clinic laboratory‑based measures, stable 
heart rhythm, and no clinical evidence of congestive heart 
failure or unstable angina. Exclusion criteria included 
pregnancy, hematological malignancy, occurrence of 
seizures, concomitant infectious or inflammatory 
processes, and acute cerebrovascular or hemorrhagic 
events.
Among 198 patients in our study, we observed that 
long‑term treatment (up to 5 years) with daily intranasal 
POH administration improved and stabilized the 
condition of 19 LGG patients. In this study presented 
here, the cohort included, after appropriate informed 
consent, 19 adult patients with LGG. Diagnosis and 
histological classification came from biopsy and were 
formally designated the LGG by the World Health 
Organization (Grade II). Adverse events were graded 
according to Common Terminology Criteria for Adverse 
Events‑Version 4.0 (CTCAE). These 19 patients did not 
undergo radiotherapy because the clinical management 
was observation and imaging control.
Drug administration and dose escalation
POH was formulated for intranasal delivery and the 
preparation supplied by the University Pharmacy was 
according to the following patents BR Application 
Number 0107262‑5 December 17, 2001. POH (Sigma 
Chem. Co., St Louis, MI, USA) 0.3% v/v POH 
(55 mg) was administered by inhalation 4 times daily. 
All patients received POH 4 times daily by intranasal 
(inhalation) delivery from initial dose (66.7/dose; totaling 
266.8 mg/daily).
Magnetic resonance imaging
Magnetic resonance imaging (MRI) was used to 
correlate the initial symptoms with clinical presentation. 
Tumor size was determined by performing axial 
contrast‑enhanced scans, where the largest perpendicular 
diameter of the enhanced lesion was used as the scale 
in order to keep the comparison constant with the same 
type of axial imaging (MRI).
RESULTS
Interaction of perillyl alcohol with plasma 
membranes
As hypothesized, all POH molecules partition into 
the lipid‑water interface with the hydrophobic part of 
the molecule interacts with the lipid acyl tails, and the 
−OH group interacts with the lipid head groups. The 
membrane dipole potential is significantly modified by 
POH [Figure 1]. The interfacial peak is slightly higher, 
but the major difference is in about 1 nm from the 
lipid bilayer center. In this region of the bilayer, POH 
can directly interact with Ras, modifying its activity, and 
ultimately influencing tumor progression. In addition, it 
is also possible that POH affects Ras by modifying the 
membrane properties such as the dipole potential.
Clinical activity of intranasal perillyl alcohol in 
low‑grade glioma patients
Our previous studies[7‑9] have demonstrated that 
intranasal administration of a p21‑Ras lipophilic inhibitor 
that easily crosses the blood‑brain barrier is a safe and 
noninvasive strategy capable of prolonging overall survival 
of recurrent malignant glioma patients considered at the 
terminal stage. Because the response survival rate among 
the patients was significantly different, we proceeded to 
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stratify patients into astrocytoma Grade II, astrocytoma 
Grade III, primary glioblastoma, and secondary 
glioblastoma. In subgroup analysis, 19 patients with 
LGG were studied. Demographic characteristics of all 
patients are presented in Table 1. Subtotal resection was 
performed in 9 patients, whereas 10 patients underwent 
stereotactic biopsy. The 19 patients have been followed 
up with a segment ranging from 4.7 to 6 years, with no 
tumor recurrence.
According to CTCAE, 2 patients had nasal aching after 
prolonged use with 133.4 mg/dose (533.6 mg/daily) 
POH. After topic treatment, POH dose was reduced 
(266.8 mg/daily) and patients improved clinical condition 
without any further complaint. Prolonged POH 
inhalation chemotherapy at 266.8 mg/daily did not cause 
cumulative toxicity, and neither altered clinical chemistry 
(hepatic, renal, and lung) nor hematological parameters. 
At the start of treatment, patients frequently reported an 
intense headache (33%); however, there were no further 
complaints of seizures, nausea, mental confusion, lack of 
memory or language deficits, visual dizziness, behavioral 
alterations, or sleepiness.
A factor that greatly influenced the overall survival and 
response of malignant glioma patients to long‑term 
intranasal POH treatment was the presence of peritumoral 
edema that contributed to clinical symptoms (intense 
headache, dizziness, focal neurological deficits, and 
seizures) and morbidity, and eventually favored glioma 
cell invasion to other brain structures. In this subgroup 
studied here, there was no presence of peritumoral 
edema in the MRI taken before patient inclusion in POH 
treatment.
Noteworthy, among 198 patients in our study, we 
observed that long‑term treatment (up to 5 years) 
with daily intranasal POH administration as a single 
chemotherapeutic drug improved and stabilized the 
condition of 19 LGG patients [Figure 2]. However, due 
to the small number of patients included, further studies 
will be required to further validate this result.
DISCUSSION
This study demonstrated that long‑term POH intranasal 
administration was well tolerated and effective in 
halting progression in LGG patients. As gliomas are 
highly multidrug resistant, and changes in physiological 
Table 1: Low‑grade gliomas in adults treated with 
inhaled Perillyl alcohol (n=19)
n Age/
gender
Symptom Initial 
treatment
Histology Tumor 
progression
1 40/female Seizures Biopsy Astro Stable
2 35/male Seizures Subtotal Oligo Regression
3 35/female Seizures Subtotal Astro Stable
4 28/male Seizures Biopsy Astro Stable
5 29/female Seizures subtotal Astro Stable
5 30/female Seizures Subtotal Astro Stable
6 35/female IH Subtotal Astro Stable
7 18/male FND Subtotal Astro Stable
8 27/male Seizures biopsy Astro Stable
9 38/male Seizures Biopsy Astro Stable
10 62/female Seizures Subtotal Astro Regression
11 31/male Seizures Biopsy Astro Stable
12 27/female Seizures Biopsy Astro Stable
13 44/male Seizures Biopsy Astro Stable
14 38/female Seizures Biopsy Astro Stable
15 39/female Seizures Subtotal Astro Stable
16 40/male Seizures Biopsy Astro Stable
17 25/male IH Subtotal Astro Stable
18 39/female Seizures Biopsy Astro Stable
19 41/female IH Subtotal Astro Stable
POH: Perillyl alcohol, IH: Intracranial hypertension, FND: Focal neurological deficit
Figure 1: (a) A snapshot from a molecular dynamic simulation of an H-Ras lipid-anchored in a dimyristoylphosphatidylcholine bilayer. 
The dimyristoylphosphatidylcholine lipids are shown in silver stick models with the noncarbon heavy atoms at the glycerol and head group 
regions colored in yellow. The H-Ras anchor is shown in a space-filling model with carbon in light green, oxygen in red, nitrogen in blue, 
and sulfur in orange. Lipid molecules that were on top of the anchor and prevented visualization were removed for clarity, as were water 
molecules and hydrogen atoms. (b) The dipole potential across a dimyristoylphosphatidylcholine bilayer in the presence and absence of 
perillyl alcohol. The potential was symmetrized around the bilayer center to correct fluctuations from bulk translation of the center of 
mass of the lipid bilayer during the simulation
ba
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parameters may be linked to their high degree of 
malignancy, this study pari passu, quantified the 
interaction of POH with a DMPC lipid bilayer. Thus, 
we aimed to explain the mechanism by which POH 
is effective primarily in tumor cells and not in normal 
cells. Our results demonstrated that POH modifies the 
dipole potential, and can thus influence the properties of 
proteins residing in the lipid bilayer such as Ras, which 
has been implicated in malignant gliomas.[35] We earlier 
showed that POH affects other properties of the lipid 
bilayer as well such as the segmental order parameter, 
area per lipid, and thickness.[34]
Thus, POH as an amphipathic drug can modulate 
membrane lipids of drug resistant cells, leading to 
alterations in the bilayer’s biophysical properties. As 
a consequence, this may facilitate drug transport and 
delivery, thereby overcoming drug resistance. As well, 
the dipole potential, with its much stronger electric 
field, may impact membrane proteins and result in 
alterations of their activity. This idea is supported by 
studies performed on the Na/K‑ATPase ion pump,[13,14] 
on phospholipase A2,[33] and on amphiphilic peptides 
located in membranes.[4] Indeed, the nonfunctioning 
of an active transport mechanism, such as the 
Na/K‑ATPase electrochemical gradient which is essential 
for a number of other cellular functions, certainly 
leads to cell death. Yet, the wide range of unspecific 
biological effects of suggests that their main effect 
may be through a physicochemical action on biological 
membranes.[11]
It is well established that an acid‑base complex 
equilibrium, involving surrounding medium and the 
lipid bilayer, determines the electrical properties of 
cellular membranes.[6] Indeed, the majority of membrane 
components, including fatty acids, different types of 
phospholipids, and a number of proteins, contribute to 
these interactions. However, a variety of physiological 
or pathological conditions, including the cellular 
transformation of cancer cells, modify the membrane 
composition of free fatty acids or phospholipids.[10,30] 
Combined, such alterations can result in significant 
changes of membrane fluidity and phospholipid turnover, 
and as a consequence impact a variety of cellular functions, 
such as activation of immune cells (phagocytosis, 
proliferation), property changes of membrane‑bound 
enzymes, and characteristics of tumor growth.[12] In 
the case of brain tumors, it is known that glioma cells 
present with reversible alterations in organization and 
distribution of intramembrane particles.[3] In this context, 
alterations in small GTPase‑mediated signal transduction 
Figure 2: Representative MRIs of LGG patients under intranasal POH treatment. One patient presented reduction of tumor size after 
3 years (b) and 6 years (c) of POH treatment in comparison with first image obtained before treatment (a) Conversely, compared with 
initial MRI (d) a second patient maintained stable disease after 3 years (e) and 5 years (f) of treatment with POH
b ca
d e f
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pathways have emerged as a central step in the molecular 
pathogenesis of gliomas.
Geranylgeranyl pyrophosphate (GGPP) and farnesyl 
pyrophosphate (FPP) are derived from mevalonate, whose 
production is catalyzed by 3‑hydroxy‑3‑methylglutaryl‑CoA 
reductase. Prenylation by FPP, as well as GGPP, is required 
for membrane insertion and oncogenic function of 
Ras‑ and Rho‑proteins triggering the stimulation of the 
Ras‑Raf‑MEK‑ERK pathway.[1] Moreover, depolarized 
plasma membrane was aligned with the MDR phenotype 
in glioma.[24,25] It is, therefore, conceivable that POH 
lipophilicity according to our study modifies the 
dipole potential and further induces apoptosis in high 
proliferating glioma cells. Although this conjecture remains 
hypothetical at this time, results of our Phase I/II clinical 
studies demonstrated that exclusive intranasal inhalation 
of POH is effective against glioma recurrence, in the 
absence of detectable toxic side events.[7‑9] The antitumor 
and chemopreventive activity of POH is a result of 
multifaceted functions suppressing inflammatory responses 
and oxidative stress, partly complemented by its potential 
ability to modify carcinogen‑metabolizing enzymes in the 
liver, and combined with its antiproliferative potency via 
inhibition of Ras proteins.
Data in literature indicates that LGG may dedifferentiate 
into a more malignant astrocytoma or glioblastoma 
multiforme, a process that appears to take place within 
approximately 5 years after the diagnosis.[32] In this 
study, a cohort of the 19 LGG patients under long‑term 
treatment (up to 5 years) with daily intranasal POH 
administration as single chemotherapy drug, stabilized 
with the improved clinical condition, and halted tumor 
progression without evidence of seizures and deterioration 
in cognitive function.
In summary, our results demonstrate that POH 
effectively enters into the cell membrane and might 
exert its multivariate clinical effects via modulation of 
the lipid bilayer components of the cellular membrane. 
This reduces the formation of tubular networks through 
inhibition of posttranslational isoprenylation of Ras. 
Consequently, intranasal administration of POH could be 
an effective novel strategy for future therapeutic efforts 
regarding prevention of dedifferentiation in LGGs and 
further make an important contribution to overcome 
induction of acquired drug resistance. We propose that 
in the near future the synthesis of biologically active 
hybrid molecules, containing POH as a carrier conjugated 
to drugs specifically targeting critical regulators of cell 
proliferation, may become a potentially effective addition 
to therapeutic regimens for brain tumors.
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